Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of New York Mellon Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Bank of New York Mellon Corp trades at $151.92 (market cap $104.27B). The key difference: Bank of New York Mellon Corp is far larger — about 2.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of New York Mellon Corp pays a 1.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BNY | |
|---|---|---|
Market Cap | $39.89B | $104.27B |
Sector | Health | Financials |
52-Week High | $491.22 | $152.91 |
52-Week Low | $278.09 | $93.72 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BNY trades at $151.92, down 0.22% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.21% net income margin and 14.81% ROE, supported by a 19% dividend increase announcement in June 2026. Analyst consensus is mixed with 38.1% buy ratings and a $156 price target, slightly above current levels.
Outlook remains positive given consistent earnings beats and digital asset expansion, but risks include high RSI levels suggesting overbought conditions and sensitivity to interest rate changes. The stock offers steady income growth with dividend hikes, yet investors should monitor execution on large investing outflows and competitive pressures in custody banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
